Cheng Qian

Cheng Qian


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2014 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
CQCheng Qian
Cheng Qian
JLJuan Liu
Juan Liu
XCXuetao Cao
Xuetao Cao

24 March 2023 in Frontiers in Immunology
Verified
Journal Article
Open access
CLChunzhen Li
Chunzhen Li
SYShu Yu
Shu Yu
JCJie Chen
Jie Chen
QHQianshan Hou
Qianshan Hou
SWSiyi Wang
Siyi Wang
SYShulei Yin
Shulei Yin
DNA damage-repair machinery participates in maintaining genomic integrity and affects tumorigenesis. Molecular signatures based on DNA damage-repair-related genes (DRGs) capable of comprehensively indicating the prognosis, tumor immunometabolic profile and therapeutic responsiveness of breast cancer (BRCA) patients are still lacking. Integrating public datasets and bioinformatics algorithms, we developed a robust prognostic signature based on 27 DRGs. Multiple patient cohorts identified significant differences in various types of survival between high- and low-risk patients stratified by the signature. The signature correlated well with clinicopathological factors and could serve as an independent prognostic indicator for BRCA patients. Furthermore, low-risk tumors were characterized by more infiltrated CD8+ T cells, follicular helper T cells, M1 macrophages, activated NK cells and resting dendritic cells, and fewer M0 and M2 macrophages. The favorable immune infiltration patterns of low-risk tumors were also accompanied by specific metabolic profiles, decreased DNA replication, and enhanced antitumor immunity. Low-risk patients may respond better to immunotherapy, and experience improved outcomes with conventional chemotherapy or targeted medicine. Real-world immunotherapy and chemotherapy cohorts verified the predictive results. Additionally, four small molecule compounds promising to target high-risk tumors were predicted. In vitro experiments confirmed the high expression of GNPNAT1 and MORF4L2 in BRCA tissues and their association with immune cells, and the knockdown of these two DRGs suppressed the proliferation of human BRCA cells. In summary, this DNA damage-repair-related signature performed well in predicting patient prognosis, immunometabolic profiles and therapeutic sensitivity, hopefully contributing to precision medicine and new target discovery of BRCA.

7 June 2021 in Cellular & Molecular Immunology
Verified
Journal Article
Closed access
PDF file
CQCheng Qian
Cheng Qian
XCXuetao Cao
Xuetao Cao

5 May 2025 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
HZHanfu Zhang
Hanfu Zhang
YYYizhi Yu
Yizhi Yu
CQCheng Qian
Cheng Qian
Background: Recent advances in immunotherapy have spotlighted macrophages as central mediators of disease treatment. Their polarization into pro‑inflammatory (M1) or anti‑inflammatory (M2) states critically influences outcomes in cancer, autoimmunity, and chronic inflammation. Oligonucleotides have emerged as highly specific, scalable, and cost‑effective agents for reprogramming macrophage phenotypes.Objective: To review oligonucleotide strategies—including ASOs, siRNAs, miRNA mimics/inhibitors, and aptamers—for directing macrophage polarization and their therapeutic implications.Review Scope: We examine key signaling pathways governing M1/M2 phenotypes, describe four classes of oligonucleotides and their mechanisms, and highlight representative preclinical and clinical applications.Key Insights: Agents such as AZD9150, MRX34, and AS1411 demonstrate macrophage reprogramming in cancer, inflammation, and infection models. Advances in ligand‑conjugated nanoparticles and chemical modifications improve delivery and stability, yet immunogenicity, off‑target effects, and formulation challenges remain significant barriers.Future Perspectives: Optimizing delivery platforms, enhancing molecular stability, and rigorous safety profiling are critical. Integration with emerging modalities—such as engineered CAR‑macrophages—will enable precise, disease‑specific interventions, and advance oligonucleotide‑guided macrophage modulation toward clinical translation.